Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Virology

• Publication date

  2002-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.76.18.9035-9045.2002PMID 12186887PMCID PMC136433
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methods in molecular medicine

  2004cited by this paper
• HIV Type 1 Group M Clades Infecting Subjects From Rural Villages in Equatorial Rain Forests of Cameroon

  2002cited by this paper
• Vaccine-Elicited V3 Loop-Specific Antibodies in Rhesus Monkeys and Control of a Simian-Human Immunodeficiency Virus Expressing a Primary Patient Human Immunodeficiency Virus Type 1 Isolate Envelope

  2001cited by this paper
• Induction and Characterization of Neutralizing Antibodies against a Human Immunodeficiency Virus Type 1 Primary Isolate

  2001cited by this paper
• V3-Specific Polyclonal Antibodies Affinity Purified from Sera of Infected Humans Effectively Neutralize Primary Isolates of Human Immunodeficiency Virus Type 1

  2001influential reference
• Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins.

  2000cited by this paper
• Conserved and Exposed Epitopes on Intact, Native, Primary Human Immunodeficiency Virus Type 1 Virions of Group M

  2000influential reference
• Immunoreactivity of Intact Virions of Human Immunodeficiency Virus Type 1 (HIV-1) Reveals the Existence of Fewer HIV-1 Immunotypes than Genotypes

  2000influential reference
• A Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 Is Determined by Distinct Mechanisms Mediating Enhanced Infectivity and Conformational Change of the Envelope Complex

  2000cited by this paper
• A Human Immunodeficiency Virus Prime-Boost Immunization Regimen in Humans Induces Antibodies That Show Interclade Cross-Reactivity and Neutralize Several X4-, R5-, and Dualtropic Clade B and C Primary Isolates

  2000influential reference
• Neutralization of HIV-1 Infection of Human Peripheral Blood Mononuclear Cells (PBMC) : Infectivity Reduction Method.

  1999cited by this paper
• Neutralization of HIV-1 Infection of Human Peripheral Blood Mononuclear Cells (PBMC) : Antibody Dilution Method.

  1999cited by this paper
• Immunotyping of Human Immunodeficiency Virus Type 1 (HIV): an Approach to Immunologic Classification of HIV

  1999cited by this paper
• Generation of Neutralizing Human Monoclonal Antibodies against Parvovirus B19 Proteins

  1999cited by this paper
• A cis proline turn linking two β-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide

  1999cited by this paper
• Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs.

  1999cited by this paper
• A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

  1998cited by this paper
• Study of the V3 Loop as a Target Epitope for Antibodies Involved in the Neutralization of Primary Isolates versus T-Cell-Line-Adapted Strains of Human Immunodeficiency Virus Type 1

  1998influential reference
• Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins

  1998cited by this paper
• SOLUTION STRUCTURE OF THE ANTIBODY-BOUND HIV-1IIIB V3 PEPTIDE

  1998cited by this paper
• Mapping of Epitopes Exposed on Intact Human Immunodeficiency Virus Type 1 (HIV-1) Virions: a New Strategy for Studying the Immunologic Relatedness of HIV-1

  1998cited by this paper
• A Human Monoclonal Antibody Specific for the V3 Loop of HIV Type 1 Clade E Cross-Reacts with Other HIV Type 1 Clades

  1998cited by this paper
• Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage

  1998cited by this paper
• Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies.

  1998influential reference
• Interactions of Polyclonal and Monoclonal Anti-Glycoprotein 120 Antibodies with Oligomeric Glycoprotein 120-Glycoprotein 41 Complexes of a Primary HIV Type 1 Isolate: Relationship to Neutralization

  1998cited by this paper
• The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain

  1997cited by this paper
• Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor

  1997influential reference
• Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.

  1997cited by this paper
• Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.

  1997cited by this paper
• Structure-based design of a constrained peptide mimic of the HIV-1 V3 loop neutralization site.

  1997cited by this paper
• Human Immunodeficiency Virus Type 1 Neutralizing Antibody Serotyping Using Serum Pools and an Infectivity Reduction Assay

  1996cited by this paper
• CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5

  1996influential reference
• Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer.

  1996cited by this paper
• CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5

  1996cited by this paper
• Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization

  1996cited by this paper
• Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG

  1995cited by this paper
• Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins.

  1995cited by this paper
• Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies

  1995cited by this paper
• A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B

  1995cited by this paper
• Defining Surrogate Serologic Tests with Respect to Predicting Protective Vaccine Efficacy: Poliovirus Vaccination

  1995cited by this paper
• Differential Role of V3-Specific Antibodies in Neutralization Assays Involving Primary and Laboratory-Adapted Isolates of HIV Type 1

  1995cited by this paper
• Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses

  1994cited by this paper
• Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

  1994cited by this paper
• Frequent and Early HIV-1MN Neutralizing Capacity in Sera from Dutch HIV-1 Seroconverters Is Related to Antibody Reactivity to Peptides from the gp120 V3 Domain

  1994cited by this paper
• Crystal structure of the principal neutralization site of HIV-1.

  1994cited by this paper
• Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains

  1994cited by this paper
• Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization

  1994influential reference
• Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.

  1994cited by this paper
• Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.

  1993cited by this paper
• Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen.

  1993cited by this paper
• Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.

  1993cited by this paper
• V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity.

  1992cited by this paper
• Carbohydrate determinant NeuAc-Gal beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120.

  1992influential reference
• Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.

  1991cited by this paper
• Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results.

  1991cited by this paper
• The human immunodeficiency virus.

  1991cited by this paper
• Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.

  1991cited by this paper
• Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies

  1991cited by this paper
• Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications

  1991cited by this paper
• Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees

  1990cited by this paper
• Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

  1989cited by this paper
• Characterization of HIV‐1 neutralization escape mutants

  1989cited by this paper
• Biologic features of HIV-1 that correlate with virulence in the host.

  1988cited by this paper
• Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

  1988cited by this paper
• Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

  1988cited by this paper
• Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

  1988cited by this paper
• Detection of monoclonal antibodies specific for carbohydrate epitopes using periodate oxidation.

  1985cited by this paper
• Construction and testing of mouse--human heteromyelomas for human monoclonal antibody production.

  1983cited by this paper

• Reduction of the HIV-1 reservoir in T cells from persons with HIV-1 on suppressive antiretroviral therapy using expanded natural killer cells ex vivo

  2022cites this paper
• Components of a HIV-1 vaccine mediate virus-like particle (VLP)-formation and display of envelope proteins exposing broadly neutralizing epitopes.

  2022cites this paper
• Functional reconstitution of the MERS CoV receptor binding motif

  2022cites this paper
• Commonly Elicited Antibodies against the Base of the HIV-1 Env Trimer Guide the Population-Level Evolution of a Structure-Regulating Region in gp41

  2022cites this paper
• Development and characterization of a panel of anti-idiotype antibodies to 1C10 that cross-neutralize HIV-1 subtype B viruses

  2022cites this paper
• Distinct conformations of the HIV-1 V3 loop crown are targetable for broad neutralization

  2021cites this paper
• Antigens

  2021cites this paper
• Polyfunctional Tier 2–Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor

  2021cites this paper
• Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1

  2021cites this paper
• Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice

  2021cites this paper
• SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles

  2020cites this paper
• Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies

  2019cites this paper
• Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1

  2019cites this paper
• Conformational Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 Bound States

  2019cites this paper
• Requirements for Empirical Immunogenicity Trials, Rather than Structure-Based Design, for Developing an Effective HIV Vaccine

  2019cites this paper
• Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies

  2019cites this paper
• Isolation and Characterization of Cross-Neutralizing Human Anti-V3 Single-Chain Variable Fragments (scFvs) Against HIV-1 from an Antigen Preselected Phage Library

  2018cites this paper
• HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

  2018cites this paper
• No evidence for cross-reactivity of virus-specific antibodies with HLA allo-antigens.

  2018cites this paper
• Display of the HIV envelope protein at the yeast cell surface for immunogen development

  2018cites this paper
• OriginalBasicScienceçGeneral No Evidence for Cross-reactivity of Virus-specific Antibodies With HLA Alloantigens

  2018cites this paper
• Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates

  2017cites this paper
• Role of envelope compactness and glycosylation in HIV-1 resistance to neutralising antibody responses

  2017cites this paper
• Chinks in the armor of the HIV-1 Envelope glycan shield: Implications for immune escape from anti-glycan broadly neutralizing antibodies.

  2017cites this paper
• Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner

  2017cites this paper
• Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory

  2016cites this paper
• What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

  2015cites this paper
• A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

  2015cites this paper
• Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity

  2015cites this paper
• Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL

  2015cites this paper
• Structural basis of clade‐specific HIV‐1 neutralization by humanized anti‐V3 monoclonal antibody KD‐247

  2015cites this paper
• Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers

  2014cites this paper
• Tomographyon Intact Viruses by Cryo-Electron in Complex with the V3 Loop Antibody Visualization of Retroviral Envelope Spikes

  2014cites this paper
• Functional Characterization of Two scFv-Fc Antibodies from an HIV Controller Selected on Soluble HIV-1 Env Complexes: A Neutralizing V3- and a Trimer-Specific gp41 Antibody

  2014cites this paper
• Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses

  2014cites this paper
• A critical question for HIV vaccine development: Which antibodies to induce?

  2014cites this paper
• Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

  2014cites this paper
• Visualization of Retroviral Envelope Spikes in Complex with the V3 Loop Antibody 447-52D on Intact Viruses by Cryo-Electron Tomography

  2014cites this paper
• Computational Prediction of Neutralization Epitopes Targeted by Human Anti-V3 HIV Monoclonal Antibodies

  2014cites this paper
• A Modern Biopharmaceutical to Treat AIDS – Challenges in Designing HIV Env Immunogens for Developing a Vaccine

  2013cites this paper
• Correction: Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization

  2013cites this paper
• Identification of the potential regions of Epap-1 that interacts with V3 loop of HIV-1 gp120.

  2013cites this paper
• Antibody-Dependent, FcγRI-Mediated Neutralization of HIV-1 in TZM-bl Cells Occurs Independently of Phagocytosis

  2013cites this paper
• HIV-1 V3 loop crown epitope-focused mimotope selection by patient serum from random phage display libraries: implications for the epitope structural features.

  2013cites this paper
• Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope

  2013cites this paper
• Diverse Recombinant HIV-1 Envs Fail To Activate B Cells Expressing the Germline B Cell Receptors of the Broadly Neutralizing Anti-HIV-1 Antibodies PG9 and 447-52D

  2013cites this paper
• Broadly neutralizing antiviral antibodies.

  2013cites this paper
• Topological Analysis of HIV-1 Glycoproteins Expressed In Situ on Virus Surfaces Reveals Tighter Packing but Greater Conformational Flexibility than for Soluble gp120

  2013cites this paper
• Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

  2013cites this paper
• Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization

  2012cites this paper
• Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors

  2012influential citation
• Antibody Guided Exploration of V3 Exposure on Subtype C HIV

  2012cites this paper
• Predefined GPGRAFY-Epitope-Specific monoclonal antibodies with different activities for recognizing native HIV-1 gp120

  2012cites this paper
• Structure-based design for high-hanging vaccine fruits.

  2012cites this paper
• In Vitro Restoration of Th17 Response During HIV Infection with an Antiretroviral Drug and Th17 Differentiation Cytokines

  2012cites this paper
• Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication

  2012cites this paper
• Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

  2012cites this paper
• Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

  2012cites this paper
• Co-Immunization with Multimeric Scaffolds and DNA Rapidly Induces Potent Autologous HIV-1 Neutralizing Antibodies and CD8+ T Cells

  2012cites this paper
• Human hybridoma technology

  2012cites this paper
• Isolation of Monoclonal Antibodies with Predetermined Conformational Epitope Specificity

  2012cites this paper
• Dynamic Antibody Specificities and Virion Concentrations in Circulating Immune Complexes in Acute to Chronic HIV-1 Infection

  2011cites this paper
• Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer

  2011cites this paper
• Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine

  2011cites this paper
• Identification and characterization of HIV-1 specific neutralizing antibodies from HIV-1 seropositive patients and autoimmune (HIV-1 seropositive or seronegative) participants.

  2011cites this paper
• Designing Immunogens for Vaccine Development in Reference to HIV

  2011cites this paper
• Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure

  2011cites this paper
• Characterisation and Kinetics of Aptamer Binding to HIV-1 Subtype C gp120

  2011cites this paper
• Immunotherapeutic restoration in HIV-infected individuals.

  2011cites this paper
• DC-SIGN Increases the Affinity of HIV-1 Envelope Glycoprotein Interaction with CD4

  2011cites this paper
• Longitudinal Study of Primary HIV-1 Isolates in Drug-Naïve Individuals Reveals the Emergence of Variants Sensitive to Anti-HIV-1 Monoclonal Antibodies

  2011cites this paper
• Cross-Clade HIV-1 Neutralizing Antibodies Induced with V3-Scaffold Protein Immunogens following Priming with gp120 DNA

  2011cites this paper
• Regulation of the susceptibility of HIV-1 to a neutralizing antibody KD-247 by nonepitope mutations distant from its epitope

  2011cites this paper
• Limitations to the structure‐based design of HIV‐1 vaccine immunogens

  2011influential citation
• Structural Conservation Predominates Over Sequence Variability in the Crown of HIV Type 1's V3 Loop

  2010cites this paper
• Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends

  2010cites this paper
• Unravelling the antigenic landscape of the HIV-1 subtype A envelope of an individual with broad cross-neutralizing antibodies using phage display peptide libraries.

  2010cites this paper
• Toward an antibody-based HIV-1 vaccine.

  2010cites this paper
• Crystal Structure and Size-Dependent Neutralization Properties of HK 20 , a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp 41

  2010cites this paper
• Conserved structural elements in the V3 crown of HIV-1 gp120

  2010cites this paper
• Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

  2010cites this paper
• Comparative Magnitude of Cross-Strain Conservation of HIV Variable Loop Neutralization Epitopes

  2010cites this paper
• Crystal Structure and Size-Dependent Neutralization Properties of HK20, a Human Monoclonal Antibody Binding to the Highly Conserved Heptad Repeat 1 of gp41

  2010cites this paper
• Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis

  2010cites this paper
• Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.

  2010cites this paper
• Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.

  2010cites this paper
• Protein conformational changes induced by adsorption onto material surfaces: an important issue for biomedical applications of material science

  2010cites this paper
• Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.

  2010cites this paper
• Dissection of HIV-1 Env-specific B cell responses in non-human primates

  2010cites this paper
• P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes

  2009cites this paper
• Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes

  2009influential citation
• Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

  2009cites this paper
• Synthetic Peptide Vaccines and the Search for Neutralization B Cell Epitopes

  2009cites this paper
• Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

  2009cites this paper
• Worldwide Distribution of HIV Type 1 Epitopes Recognized by Human Anti-V3 Monoclonal Antibodies

  2009cites this paper
• Deglycosylation or Partial Removal of HIV-1 CN54 gp140 V1/V2 Domain Enhances Env-Specific T Cells

  2009cites this paper
• Characterization of a Human Immunodeficiency Virus Type 1 V3 Deletion Mutation That Confers Resistance to CCR5 Inhibitors and the Ability To Use Aplaviroc-Bound Receptor

  2009cites this paper
• Characterisation of llama antibody fragments able to act as HIV-1 entry inhibitors

  2009influential citation
• [Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].

  2009cites this paper
• Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.

  2009cites this paper